The Gross Law Firm Reminds Ultragenyx Investors of Pending Class Action Lawsuit

Shareholders who purchased shares during the class period are encouraged to contact the firm about potential lead plaintiff appointment.

Published on Feb. 23, 2026

Got story updates? Submit your updates here. ›

The Gross Law Firm has issued a notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) regarding a pending class action lawsuit. Shareholders who purchased shares of RARE during the class period are encouraged to contact the firm about potentially being appointed as lead plaintiff, though lead plaintiff appointment is not required to participate in any recovery.

Why it matters

Class action lawsuits allow shareholders to collectively seek damages or other remedies from a company they believe has violated securities laws or made misleading statements. As a leading pharmaceutical company, any legal issues faced by Ultragenyx could impact investor confidence and the stock price.

The details

The Gross Law Firm has issued a notice to Ultragenyx Pharmaceutical Inc. shareholders regarding a pending class action lawsuit. Shareholders who purchased RARE stock during the class period are being encouraged to contact the firm about potentially being appointed as lead plaintiff in the case, though lead plaintiff status is not required to participate in any recovery.

  • The class period for the lawsuit is not specified in the source article.

The players

The Gross Law Firm

A law firm issuing the notice to Ultragenyx shareholders about the pending class action lawsuit.

Ultragenyx Pharmaceutical Inc.

A pharmaceutical company (NASDAQ: RARE) facing a class action lawsuit from its shareholders.

Got photos? Submit your photos here. ›

The takeaway

This case highlights the potential legal risks and shareholder actions that publicly traded pharmaceutical companies can face, which can impact investor confidence and the stock price if not properly addressed.